Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397241 | 0.82 | CYP2C9 (0.38) | TSHRCTSK | |
| SCHEMBL20669273 | 0.78 | CTSK (0.37) | CTSK | |
| SCHEMBL22030207 | 0.75 | CAPN1 (0.40) | CTSK | |
| SCHEMBL18578916 | 0.75 | CAPN1 (0.40) | CTSK | |
| SCHEMBL13397660 | 0.74 | RECQL (0.32) | RECQLTSHR | |
| SCHEMBL13397560 | 0.74 | TSHR (0.34) | RECQLTSHR | |
| SCHEMBL31732378 | 0.74 | MME (0.39) | RECQLTSHR | |
| SCHEMBL23446206 | 0.72 | CTSK (0.33) | CTSK | |
| SCHEMBL23446261 | 0.72 | LMNA (0.34) | CTSK | |
| SCHEMBL16359853 | 0.72 | PAX8 (0.44) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-7652153-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | RECQL 2588/4885TSHR 4831/4885CTSK 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.